Elicio Therapeutics closed at $1.56 on Nov 4, up 2.63%, within 2.6% of its 52-week closing low. Volume of 290.0K shares was 0.97× its 20-day average (close to normal).
Split-adjusted performance: -17.0% over one month, -85.1% over six months, -83.1% over one year.
Short interest was 1.7M shares at the Oct 15 settlement, up 9.7% from the prior report (9.0% of float, 7.3 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ELTXElicio Therapeutics | $1.56 | +2.63% | −85.1% | — | — | — | $42.3M | |
| SERSerina Therapeutics | $1.69 | −7.65% | −7.7% | −100.0% | — | — | $42.9M | Compare |
| ATNMActinium Pharmaceuticals | $1.41 | +0.71% | +13.7% | — | 79.7% | 3.9 | $44.3M | Compare |
| BMEABiomea Fusion | $0.6119 | −1.91% | −61.8% | — | — | — | $44.4M | Compare |
| DWTXDogwood Therapeutics | $1.03 | −0.96% | −37.6% | — | — | — | $39.4M | Compare |
| ALDXAldeyra Therapeutics | $0.6474 | +4.32% | −62.8% | — | — | — | $39.1M | Compare |
| HYPDHyperion DeFi | $3.07 | +0.66% | −15.7% | — | 4009.1% | — | $46.7M | Compare |
| SCYXSCYNEXIS | $3.84 | −2.54% | −51.1% | −82.8% | 3147.7% | — | $38.2M | Compare |
| GRCEGrace Therapeutics | $1.81 | −1.63% | −23.6% | — | — | — | $38.1M | Compare |
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
